At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,968 enrolled
Drug / intervention
Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults
In Brief
A Phase 3 clinical trial evaluating Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ), MenACWY-CRM conjugate vaccine, and 1 other intervention for N. Meningitidis Carriage. Completed, enrolled 2,968 participants across 10 sites.
Detailed Summary
The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal vaccines on carriage of Neisseria meningitidis in a young adult population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsN. Meningitidis Carriage
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionJan 2012
TodayJul 2026
First PostedOct 5, 2010
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.7 years ago
Interventions
Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)biological
MenACWY-CRM conjugate vaccinebiological
Japanese Encephalitis vaccinebiological